Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

By Laliberté François   Pilon Dominic   Raut Monika K.   Nelson Winnie W.   Olson William H.   Germain Guillaume   Schein Jeff R.   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 645-653

Informa Healthcare

Access to resources Recommend Favorite

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

By Schoof Nils   Schnee Janet   Schneider Gary   Gawlik Melissa   Zint Kristina   Clemens Andreas   Bartels Dorothee B.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 795-804

Informa Healthcare

Access to resources Recommend Favorite

Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation

By Amin Alpesh   Stokes Michael   Wu Ning   Gatt Elyse   Makenbaeva Dinara   Wiederkehr Daniel   Boulanger Luke  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1193-1202

Informa Healthcare

Access to resources Recommend Favorite

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

By Heidbuchel Hein   Verhamme Peter   Alings Marco   Antz Matthias   Hacke Werner   Oldgren Jonas   Sinnaeve Peter   Camm A. John   Kirchhof Paulus  

EP-Europace, Vol. 15, Iss. 5, 2013-05 ,pp. : 625-651

Oxford University Press

Access to resources Recommend Favorite

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 8, 2015-08 ,pp. : 1405-1413

John Wiley & Sons Inc

Access to resources Recommend Favorite